Crescita Therapeutics Inc (TSE:CTX) insider Knight Therapeutics Inc. sold 20,000 shares of Crescita Therapeutics stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of C$1.10, for a total value of C$22,000.00. Following the completion of the transaction, the insider now owns 1,935,489 shares of the company’s stock, valued at approximately C$2,129,037.90.

Knight Therapeutics Inc. also recently made the following trade(s):

  • On Friday, August 2nd, Knight Therapeutics Inc. sold 750,000 shares of Crescita Therapeutics stock. The stock was sold at an average price of C$1.00, for a total value of C$750,000.00.
  • On Tuesday, July 23rd, Knight Therapeutics Inc. sold 5,000 shares of Crescita Therapeutics stock. The stock was sold at an average price of C$1.05, for a total value of C$5,250.00.
  • On Tuesday, July 16th, Knight Therapeutics Inc. sold 10,000 shares of Crescita Therapeutics stock. The stock was sold at an average price of C$1.09, for a total value of C$10,925.00.

Shares of Crescita Therapeutics stock traded down C$0.02 on Tuesday, reaching C$0.97. The company had a trading volume of 20,062 shares, compared to its average volume of 42,556. The firm has a market capitalization of $21.44 million and a price-to-earnings ratio of 7.21. The company has a current ratio of 3.90, a quick ratio of 3.15 and a debt-to-equity ratio of 27.41. The firm’s 50-day simple moving average is C$0.96. Crescita Therapeutics Inc has a 1 year low of C$0.39 and a 1 year high of C$1.23.

Crescita Therapeutics Company Profile

Crescita Therapeutics Inc, a dermatology company, provides non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases, and their symptoms in Canada, Europe, the United States, and internationally. It owns various proprietary drug delivery platforms, including DuraPeel and MMPE that support the development of patented formulations, which facilitate the delivery of active drugs into or through the skin.

Featured Article: What does cost of debt say about a company’s financial health?

Receive News & Ratings for Crescita Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescita Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.